NASDAQ:LIXT Lixte Biotechnology (LIXT) Stock Price, News & Analysis $4.36 -0.13 (-2.90%) As of 01:11 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lixte Biotechnology Stock (NASDAQ:LIXT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lixte Biotechnology alerts:Sign Up Key Stats Today's Range$3.96▼$4.5550-Day Range$2.44▼$4.4952-Week Range$0.64▼$6.26Volume56,155 shsAverage Volume59,791 shsMarket Capitalization$50.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles. Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms. These candidates are currently advancing through early-phase clinical trials in solid tumors, where Lixte is evaluating safety, tolerability and preliminary measures of anti-tumor activity. Research and development activities are conducted in collaboration with academic institutions and contract research organizations to leverage cutting-edge science and streamline the path to clinic. Headquartered in the United States, Lixte Biotechnology maintains its R&D operations in California and works with strategic partners to extend its global reach. The company’s leadership team comprises seasoned executives and scientists with extensive experience in oncology drug development, regulatory affairs and commercial strategy. Through disciplined pipeline management and targeted clinical development, Lixte aims to deliver differentiated therapies that address significant unmet needs in cancer care.AI Generated. May Contain Errors. Read More Lixte Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreLIXT MarketRank™: Lixte Biotechnology scored higher than 8% of companies evaluated by MarketBeat, and ranked 829th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingLixte Biotechnology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageLixte Biotechnology has received no research coverage in the past 90 days.Read more about Lixte Biotechnology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Lixte Biotechnology is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lixte Biotechnology is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLixte Biotechnology has a P/B Ratio of 3.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lixte Biotechnology's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.31% of the float of Lixte Biotechnology has been sold short.Short Interest Ratio / Days to CoverLixte Biotechnology has a short interest ratio ("days to cover") of 0.81, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lixte Biotechnology has recently decreased by 34.29%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLixte Biotechnology does not currently pay a dividend.Dividend GrowthLixte Biotechnology does not have a long track record of dividend growth. News and Social MediaN/ANews SentimentN/A Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lixte Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders9.50% of the stock of Lixte Biotechnology is held by insiders.Percentage Held by Institutions5.10% of the stock of Lixte Biotechnology is held by institutions.Read more about Lixte Biotechnology's insider trading history. Receive LIXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lixte Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LIXT Stock News HeadlinesLIXTE Biotechnology Holdings (LIXT) Unlocking New Potential in Precision Cancer TreatmentApril 28, 2026 | finance.yahoo.comLixte Biotechnology Updates Executive Equity Compensation With RSUsApril 17, 2026 | tipranks.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.May 6 at 1:00 AM | American Alternative (Ad)LIXTE Biotechnology (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO ConferenceApril 13, 2026 | usatoday.comFavorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care ConferenceApril 13, 2026 | globenewswire.comLixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic PartnershipsApril 10, 2026 | finance.yahoo.comLixte Biotechnology Holdings, Inc.April 7, 2026 | cnn.comLIXTE Biotechnology Holdings (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational YearApril 4, 2026 | usatoday.comSee More Headlines LIXT Stock Analysis - Frequently Asked Questions How have LIXT shares performed this year? Lixte Biotechnology's stock was trading at $3.93 at the beginning of 2026. Since then, LIXT shares have increased by 5.0% and is now trading at $4.1250. How were Lixte Biotechnology's earnings last quarter? Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) issued its quarterly earnings results on Wednesday, November, 12th. The company reported ($0.33) earnings per share (EPS) for the quarter. When did Lixte Biotechnology's stock split? Shares of Lixte Biotechnology reverse split on Monday, June 5th 2023.The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Lixte Biotechnology IPO? Lixte Biotechnology (LIXT) raised $7 million in an initial public offering on Wednesday, November 25th 2020. The company issued 1,500,000 shares at a price of $4.75 per share. WestPark Capital and WallachBeth Capital served as the underwriters for the IPO. How do I buy shares of Lixte Biotechnology? Shares of LIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lixte Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lixte Biotechnology investors own include Predictive Oncology (POAI), Sangamo Therapeutics (SGMO), Ford Motor (F), Insulet (PODD), Energy Select Sector SPDR Fund (XLE), Zomedica (ZOM) and Abbott Laboratories (ABT). Company Calendar Last Earnings11/12/2025Today5/06/2026Next Earnings (Estimated)5/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, LIXT's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LIXT CIK1335105 Webwww.lixte.com Phone(631) 830-7092Fax631-982-5050Employees4Year Founded2006Profitability EPS (Trailing Twelve Months)($1.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.01 million Net MarginsN/A Pretax MarginN/A Return on Equity-242.85% Return on Assets-115.18% Debt Debt-to-Equity RatioN/A Current Ratio3.88 Quick Ratio3.88 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book3.98Miscellaneous Outstanding Shares11,620,000Free Float10,514,000Market Cap$48.57 million OptionableNot Optionable Beta1.04 Social Links 10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:LIXT) was last updated on 5/6/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredBigger than SpaceX, Tesla, xAI combined?!The Wall Street legend who recommended Tesla in 2012 before its 16,724% move reveals... Musk's 2026 Project...The Oxford Club | SponsoredGet Ahead of Asia's Market Wave U.S. Solar Growth with PMAX.Powell Max Limited (NASDAQ: PMAX) operates at the center of Hong Kong's $4.5 trillion capital markets, providi...Smallcaps Daily | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.When the PC replaced the mainframe, companies that missed the shift went bankrupt. George Gilder - who called ...Eagle Publishing | SponsoredHow to collect $1,170/month from silverThere is a silver fund paying up to 20% in yearly distributions - no mining stocks, no options required. The s...Investors Alley | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
